These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30927439)

  • 1. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.
    Hirakawa A; Sudo K; Yonemori K; Sadachi R; Kinoshita F; Kobayashi Y; Okuma HS; Kawachi A; Tamura K; Fujiwara Y; Rubinstein L; Takebe N
    Clin Pharmacol Ther; 2019 Oct; 106(4):803-809. PubMed ID: 30927439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.
    Xu R; Wang Q
    J Biomed Inform; 2015 Jun; 55():64-72. PubMed ID: 25817969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
    Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents.
    Castellanos EH; Chen SC; Drexler H; Horn L
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1490-5. PubMed ID: 26656518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
    Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
    Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating global treatment toxicity burden from adverse-event data.
    Lee SM; Hershman DL; Miao J; Zhong X; Unger JM; Cheung YKK
    Cancer; 2018 Feb; 124(4):858-864. PubMed ID: 29112232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.
    Wang Z; Yang X; Wang J; Wang S; Mao X; Li M; Zhao Y; Wang W; Qi X; Wu T
    J Cancer Res Ther; 2019; 15(7):1435-1449. PubMed ID: 31939421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
    Fischer-Cartlidge EA
    Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.
    Sasahara Y; Narimatsu H; Fukao A; Yoshioka T
    Int J Clin Oncol; 2016 Oct; 21(5):1004-1013. PubMed ID: 27105626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to report toxicity associated with targeted therapies?
    Cabarrou B; Boher JM; Bogart E; Tresch-Bruneel E; Penel N; Ravaud A; Escudier B; Mahier Ait-Oukhatar C; Delord JP; Roché H; Filleron T
    Ann Oncol; 2016 Aug; 27(8):1633-8. PubMed ID: 27217543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
    Altzerinakou MA; Collette L; Paoletti X
    J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
    Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
    J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
    Postel-Vinay S; Gomez-Roca C; Molife LR; Anghan B; Levy A; Judson I; De Bono J; Soria JC; Kaye S; Paoletti X
    J Clin Oncol; 2011 May; 29(13):1728-35. PubMed ID: 21444876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
    Basu B; Vitfell-Pedersen J; Moreno Garcia V; Puglisi M; Tjokrowidjaja A; Shah K; Malvankar S; Anghan B; de Bono JS; Kaye SB; Molife LR; Banerji U
    Oncology; 2012; 83(4):177-82. PubMed ID: 22889980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms for vascular complications of targeted cancer therapies.
    Gopal S; Miller KB; Jaffe IZ
    Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular toxicity of targeted therapies.
    Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
    J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.
    Mariano C; Francl M; Pope J; Wong L; Lim HJ; Lohrisch C
    Clin Breast Cancer; 2015 Feb; 15(1):73-9. PubMed ID: 25445420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.